Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
Tuesday, June 16, 2026Johnson Johnson NYSE JNJ the Company healthcares leading most comprehensive innovation powerhouse today announced an investment of more than billion in Jacksonville Florida
XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
Thursday, June 11, 2026XtalPi HK a leading platform in artificial intelligence AI and roboticsdriven drug discovery today announced a strategic partnership with a prominent international biopharmaceutical company
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
Thursday, June 11, 2026Elixiron Immunotherapeutics TPEx a clinicalstage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases today announced positive interim results
Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium in sepsis
Wednesday, June 10, 2026Matisse Pharmaceuticals BV a clinical stage company developing a medicinal product for the treatment of sepsis today announced that the US Food and Drug Administration FDA has granted Fast Track Designation
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
Tuesday, June 09, 2026Amphista Therapeutics the Company or Amphista a leader in the discovery and development of next generation targeted protein degradation TPD medicines today announces that the US Food and Drug Administration
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Tuesday, June 09, 2026The European Commission has approved Sarclisa isatuximab subcutaneous SC in combination with standardofcare regimens for the treatment of patients with multiple myeloma MM across all existing indications
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Friday, June 05, 2026Gilead Sciences Inc Nasdaq GILD and Lakefront Biotherapeutics NV Euronext Nasdaq LKFT today announced the successful completion of the previously announced acquisition of Ouro Medicines
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
Friday, June 05, 2026Mabwell SH HK an innovationdriven biopharmaceutical company with a fully integrated industry chain announced that its independently developed innovative antibody drug MW
Cubis® III: Compliant weighing, direct integration, and scalable connectivity, without extra software
Friday, June 05, 2026Sartorius launches Cubis III the latest innovation in its premium line of lab balances delivering compliant connected weighing without relying on extra software typically required to bridge instruments
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S
Thursday, June 04, 2026MEDIPOST a fully integrated commercial stage cell therapy biotechnology company announced today that it has secured the FDAs agreement to conduct a single pivotal Phase study for CARTISTEM in the US
